SCHEMBL4050105

SCHEMBL4050105

Fc1ccc(-c2n[c]c[nH]2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.40
CYP2B6 P20813 3/20 0.40
CYP2E1 P05181 1/20 0.40
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP11B2 P19099 2/20 0.34
MAPT P10636 5/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
JAK2 O60674 1/20 0.33
RET P07949 1/20 0.33
KDR P35968 1/20 0.33
GSK3A P49840 1/20 0.33
RPS6KA3 P51812 1/20 0.33
LIMK1 P53667 1/20 0.33
MAP2K1 Q02750 1/20 0.33
DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651262 0.71 IDO1 (0.45) MAPTCLK4
SCHEMBL4053490 0.71 CYP2A6 (0.40) CYP2A6CYP2B6CYP2E1CYP3A4CYP2C19
SCHEMBL26104326 0.71 CYP2A6 (0.64) CYP2A6CYP2B6CYP2E1CYP3A4CYP2C19
SCHEMBL2651748 0.69 NOTUM (0.34)
SCHEMBL4051532 0.68 MAPT (0.33) MAPTMAPK14GRM5
SCHEMBL25196918 0.66 CYP2A6 (0.38) CYP2A6CYP2B6CYP2E1CYP3A4CYP2C19
SCHEMBL1119419 0.66 SCN2A (0.33)
SCHEMBL6002502 0.66 AHR (0.46) MAPT
SCHEMBL19052440 0.65 NPY5R (0.47)
SCHEMBL4051788 0.64 CYP2A6 (0.40) CYP2A6CYP2B6CYP2E1CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R CYP2A6 1264/4885CYP2B6 885/4885CYP2E1 975/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R CYP2A6 1419/4885CYP2B6 949/4885CYP2E1 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.